BACKGROUND: Crohn's anal fistulas are common and cause considerable morbidity. Their management is often difficult; medical and surgical treatments rarely lead to true healing with frequent recurrence and complications. AIM: To examine medical treatments previously and currently used, surgical techniques and the important role of optimal imaging. METHODS: We conducted a literature search in the Pub Med database using Crohn's, Anal Fistula, Surgery, Imaging and Medical Treatment as search terms. RESULTS: Antibiotics and immunosuppressants have a role, but slow initial response, side effects and relatively low remission rates of up to around a third with frequent recurrence limit their value. Long-term infliximab produces clinical remission in 36-58% of patients with combined medical and surgical management achieving optimal outcomes. Traditional and newer surgical procedures often have a high rate of recurrence with a significant risk of temporary or, in up to 10% of cases, permanent stomas, incontinence and unhealed or slowly healing wounds in 30%. CONCLUSIONS: Management of Crohn's anal fistulas remains challenging. Established principles are to drain infection, use setons as required, aggressively manage active proctitis, give antibiotics, immunosuppressants and employ anti-TNFα therapy, and they demand significant co-operation between gastroenterologists and surgeons.
BACKGROUND: Crohn's anal fistulas are common and cause considerable morbidity. Their management is often difficult; medical and surgical treatments rarely lead to true healing with frequent recurrence and complications. AIM: To examine medical treatments previously and currently used, surgical techniques and the important role of optimal imaging. METHODS: We conducted a literature search in the Pub Med database using Crohn's, Anal Fistula, Surgery, Imaging and Medical Treatment as search terms. RESULTS: Antibiotics and immunosuppressants have a role, but slow initial response, side effects and relatively low remission rates of up to around a third with frequent recurrence limit their value. Long-term infliximab produces clinical remission in 36-58% of patients with combined medical and surgical management achieving optimal outcomes. Traditional and newer surgical procedures often have a high rate of recurrence with a significant risk of temporary or, in up to 10% of cases, permanent stomas, incontinence and unhealed or slowly healing wounds in 30%. CONCLUSIONS: Management of Crohn's anal fistulas remains challenging. Established principles are to drain infection, use setons as required, aggressively manage active proctitis, give antibiotics, immunosuppressants and employ anti-TNFα therapy, and they demand significant co-operation between gastroenterologists and surgeons.
Authors: Nicolas Schlegel; Mia Kim; Joachim Reibetanz; Katica Krajinovic; Christoph-Thomas Germer; Christoph Isbert Journal: Int J Colorectal Dis Date: 2015-04-08 Impact factor: 2.571
Authors: Yong Beom Cho; Kyu Joo Park; Sang Nam Yoon; Kee Ho Song; Do Sun Kim; Sang Hun Jung; Mihyung Kim; Hee Young Jeong; Chang Sik Yu Journal: Stem Cells Transl Med Date: 2015-03-31 Impact factor: 6.940
Authors: F de la Portilla; F Alba; D García-Olmo; J M Herrerías; F X González; A Galindo Journal: Int J Colorectal Dis Date: 2012-09-29 Impact factor: 2.571
Authors: Anuradha Shenoy-Bhangle; Katherine Nimkin; Dana Goldner; William F Bradley; Esther J Israel; Michael S Gee Journal: Pediatr Radiol Date: 2013-09-05